Hologic Inc - HOLX STOCK NEWS

Hologic, Inc. (NASDAQ: HOLX) will showcase its breast and skeletal health products, including the new Affirm Contrast Biopsy technology, at the RSNA 2022 meeting in Chicago from Nov. 27 to Dec. 1. This technology offers a cost-effective alternative to traditional breast MRI for biopsy procedures, addressing the needs of clinicians and patients. A recent study indicated that 98% of patients had a positive experience using the software. Hologic is committed to advancing breast care through innovative solutions and will also host educational symposiums on related topics.

Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 5^th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time. The fire-side chat will be streamed live and can be accessed through the investor section of Hologic's website. The webcast will remain available for 30 days post-event. Hologic specializes in innovative medical technology, focusing on enhancing women's health through early detection and treatment.

Hologic, Inc. (Nasdaq: HOLX) has announced that its 3Dimensions™ mammography system received EUREF Type Test certification, making it the first digital breast tomosynthesis system to achieve this distinction. This certification verifies that the system meets stringent European standards for image quality and radiation exposure. The 3Dimensions system provides enhanced patient comfort, improved workflow for radiologists, and is recognized for its high resolution and speed. This achievement highlights Hologic's commitment to advancing women's health through innovative technology.

Hologic, Inc. (NASDAQ: HOLX) has secured a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to enhance its SARS-CoV-2 diagnostics. This funding aims to align Hologic's Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Aptima® SARS-CoV-2 assay with FDA in vitro diagnostic standards. The Panther Fusion assay, currently under U.S. development after receiving CE-marking in May 2022, will further clinical efforts for nasal sample claims and market authorization for asymptomatic COVID-19 testing.

Hologic, Inc. (HOLX) reported Q4 FY2022 revenue of $953 million, a 27.6% decline from the previous year, yet outperforming guidance of $840-870 million. GAAP diluted EPS was $0.47, down 63.3%, while non-GAAP diluted EPS was $0.82, down 49.1%. Diagnostics revenue fell 37.8%, chiefly due to decreased COVID-19 assay sales. Despite the challenges, organic growth in Molecular Diagnostics (up 17.2%) and a 9.3% rise in Surgical revenue were notable. For FY2023, guidance anticipates revenue between $3.7 billion and $3.9 billion, reflecting continued strength in core businesses.

Hologic, Inc. (NASDAQ: HOLX) will release its fourth quarter fiscal 2022 financial results on October 31, after market close. The management will host a conference call at 4:30 p.m. Eastern Time on the same day. Interested parties can join the call by dialing designated numbers or via a provided link. A replay will be available for listening until November 30, 2022. Hologic focuses on improving women's health through innovative medical technology and treatment solutions.

Hologic Inc. rang the Nasdaq opening bell to commence Breast Cancer Awareness Month, marking the 16th occasion for this event. The company emphasized the importance of regular screenings, highlighting that over 2 billion women worldwide did not undergo cancer screenings in the past year. Tennis legend Martina Navratilova, a breast cancer survivor, joined Hologic's leadership to stress preventive care. The ongoing partnership with the Women’s Tennis Association aims to promote women's health awareness during tournaments and special events.

The second annual Hologic Global Women’s Health Index reveals that over 1.5 billion women lack necessary health screenings, including cancer and diabetes. The report highlights significant barriers to women's health, including food insecurity, safety threats, and educational gaps. The average global health score was just 53 out of 100, with Taiwan leading at 70 and Afghanistan at the lowest with 22. The Index stresses the need for better preventive care, addressing emotional health, and enhancing socioeconomic equity to improve women’s wellbeing.

Hologic, Inc. (NASDAQ: HOLX) announced its participation in two upcoming investor conferences. The first is Wells Fargo’s Healthcare Conference on September 7 at 9:45 a.m. ET, followed by Morgan Stanley’s 20th Annual Global Healthcare Conference on September 13 at 12:20 p.m. ET. Both presentations will be webcast live and available for 30 days post-event through Hologic's investor website. Hologic is dedicated to enhancing women’s health through early detection and treatment.